Georgetown University Lombardi Comprehensive Cancer Center Support Grant

摘要 乔治敦隆巴迪综合癌症中心(LCCC)是NCI指定的唯一一家综合癌症中心 总部设在美国首都的癌症中心。自2008年以来，在Louis M.Weiner博士的领导下，LCCC的愿景是防止 并以局部聚焦和全球影响治愈癌症。我们的使命是通过链接来预防、治疗和治愈癌症 科学发现、专家和富有同情心的病人护理、优质教育以及与 社会，以人为本的原则为指导，“关爱整个人”。LCCC的战略目标 是1)推进变革性癌症研究，2)减少癌症的影响和缩小我们的 集水区，3)引领高影响力的临床研究，4)确保长期增长，活力和稳定的 研究企业；5)培养下一代癌症科学家、临床医生和教育工作者。这些 LCCC与约翰·特雷尔癌症中心(JTCC)不断深化的关系进一步推动了目标的实现 Hackensack子午线健康(HMH)，一个临床和临床研究的巨擘，带来了大量的 研究基础，扩大了LCCC的影响力。通过此P30竞争续订申请，LCCC作为 CCSG与JTCC组成的财团，满足CCSG FOA的外部资金要求。LCCC财团 由总部设在华盛顿特区的乔治敦隆巴迪综合癌症中心(LCCC-DC)组成 以及位于新泽西州哈肯萨克(LCCC-NJ)的Hackensack子午线健康中心的John Theurer癌症中心。 因此，LCCC集水区由LCCC-DC和LCCC-NJ集水区界定。LCCC 研究基于四个研究项目：乳腺癌(BC)、癌症预防和控制(CPC)、 实验治疗学(ET)和分子肿瘤学(MO)数据科学领域的交叉倡议，少数人 健康和健康差距、癌症精准医学、免疫疗法和癌症生存焦点 支持这些方案的工作。在当前的CCSG资金周期中，LCCC采用了强有力的战略 规划过程，以发展和完善其研究。LCCC进行的研究正在改变实践， 范式转变和政策信息，114名成员在会议期间发表了1390篇论文(18%使用IF&GT；8) 当前CCSG资助期。目前为LCCC成员提供的专注于癌症的年度直接成本资助是 36,696,492美元(其中3,282,510美元来自LCCC-NJ的成员)。LCCC有2,165个介入临床 2014-2017年在其DC集水区的试用收益，该集水区由DC的400多万人组成 以及马里兰州和弗吉尼亚州周围的每个县。LCCC的卑尔根县新泽西州集水区包括 近100万居民。LCCC通过提供以下服务，增加了临床研究和护理的机会 大的、种族和民族多样化的集水区，这些地区因乳腺癌、前列腺癌、 胰腺癌和肝癌。未来的计划包括扩大针对集水区需求的研究， 特别侧重于血液系统恶性肿瘤和细胞治疗的翻译和临床研究。

ABSTRACT The Georgetown Lombardi Comprehensive Cancer Center (LCCC) is the only NCI-designated comprehensive cancer center based in the nation’s capital. Led by Louis M. Weiner MD since 2008, LCCC’s vision is to prevent and cure cancer with a local focus and global impact. Our mission is to prevent, treat, and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis, “care for the whole person.” LCCC’s strategic objectives are to 1) advance transformative cancer research, 2) reduce the impact of cancer and diminish disparities in our catchment area, 3) lead high-impact clinical research, 4) ensure long-term growth, vibrancy and stability of the research enterprise, and 5) develop the next generation of cancer scientists, clinicians and educators. These objectives were furthered by LCCC’s deepening relationship with the John Theurer Cancer Center (JTCC) of Hackensack Meridian Health (HMH), a clinical and clinical research powerhouse that brings a substantial research base and extends LCCC’s impact. With this P30 competitive renewal application LCCC is applying as a CCSG consortium with JTCC, which meets CCSG FOA external funding requirements. The LCCC Consortium is comprised of Georgetown Lombardi Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC-NJ catchment areas. LCCC research is based in four research programs: Breast Cancer (BC), Cancer Prevention and Control (CPC), Experimental Therapeutics (ET) and Molecular Oncology (MO). Crosscutting initiatives in data science, minority health and health disparities, cancer precision medicine, immunotherapy and cancer survivorship focus and support the work of these programs. During the current CCSG funding cycle, LCCC employed a robust strategic planning process to develop and refine its research. LCCC conducts research that is practice changing, paradigm shifting and policy informing, with 114 members publishing 1,390 papers (18% with IF>8) during the current CCSG funding period. Current cancer-focused annual direct cost funding for LCCC members is $36,696,492 (of which $3,282,510 is from members based at LCCC-NJ). LCCC had 2,165 interventional clinical trial accruals from 2014-2017 in its DC catchment area, which consists of more than four million people in DC and each surrounding county in Maryland and Virginia. LCCC’s Bergen County NJ catchment area contains nearly 1 million residents. LCCC has increased opportunities for clinical research and care by serving these large, racially and ethnically diverse catchment areas, which suffer from excess mortality from breast, prostate, pancreas and liver cancers. Future plans include expansion of research addressing catchment areas’ needs, with a particular emphasis on hematologic malignancies and cellular therapy translational and clinical research.